Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer

This study has been completed.
Sponsor:
Collaborators:
Celgene Corporation
Beth Israel Deaconess Medical Center
Massachusetts General Hospital
Information provided by (Responsible Party):
Harold J. Burstein, MD, PhD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00308178
First received: March 28, 2006
Last updated: February 15, 2013
Last verified: February 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2008
  Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)